By binding to GLP-1 receptors, these medications enhance glucose-dependent insulin secretion from pancreatic beta cells, suppress inappropriate glucagon release, slow gastric emptying, and promote satiety through central nervous system pathways
Alternative Names: Spadin Analog, PE2228, TREK-1 Antagonist, PE 22 28, Sortilin Derivative Studies and Research Data PE-22-28 Interactions with TREK-1 Channels PE-22-28 has been linked to TREK-1 receptors, a class of two-pore potassium channels
After diabetic patients reported weight loss benefits from the semaglutide, Novo Nordisk developed Wegovy, another semaglutide specifically for people trying to lose weight
In April 2023, KFF fielded a survey to a nationally representative sample of 1,479 adults in the United States from the SSRS Opinion Panel to obtain population estimates of GLP-1 agonist knowledge, attitudes, and use (Montero et al., 2024)
GLP-1 injections are, of course, a remarkable tool for anybody with diabetes, insulin resistance, or metabolic disease